ABSTRACT
Objective: to compare the in vitro efficacy of doripenem and imipenem against multi-drug resistant [MDR] Pseudomonas aeruginosa from various clinical specimens
Study Design: descriptive cross-sectional study
Place and Duration of Study: department of Microbiology, Armed Forces Institute of Pathology, Rawalpindi, from November 2012 to November 2013
Methodology: MDR Pseudomonas aeruginosa isolates from various clinical samples were included in the study. Susceptibility of Pseudomonas aeruginosa against doripenem and imipenem was performed by E-test strip and agar dilution methods. The results were interpreted as recommended by Clinical Laboratory Standard Institute [CLSI] guidelines
Results: the maximum number of Pseudomonas aeruginosa were isolated from pure pus and pus swabs. In vitro efficacy of doripenem was found to be more effective as compared to imipenem against MDR Pseudomonas aeruginosa with both E-test strip and agar dilution methods. Overall, p-values of 0.014 and 0.037 were observed when susceptibility patterns of doripenem and imipenem were evaluated with E-test strip and agar dilution methods
Conclusion: in vitro efficacy of doripenem was found to be better against MDR Pseudomonas aeruginosa as compared to imipenem when tested by both E-test and agar dilution methods
ABSTRACT
To determine antimicrobial susceptibility pattern of methicillin resistant Staphylococcus aureus in a tertiary care setting. Descriptive study. Microbiology Department, Armed Forces Institute of Pathology, Rawalpindi from March 2011 to April 2012. Two hundred isolates of MRSA recovered from various clinical specimens sent to AFIP for culture and sensitivity were identified using standard microbiological techniques and the antimicrobial susceptibility was carried out employing Kirby-Bauer disc diffusion technique as recommended by Clinical and Laboratory Standards Institute. The Susceptibility pattern of isolates was recorded in percentages. Of the 200 MRSA isolated, all[100%] were susceptiblr to vancomycin and Linezolid followed by 88% to tigecycline, 81% to chloramphenicol, 66% to amikacin, 62.5% to clindamycin, 52.5% to doxycycline, 36% to trimethoprim-sulfamethoxazole, 29% to gentamicin, 28.5% to erythromycin and 26.5% to ciprofloxacin. The results show that linezolid and vacomycin hold excellent in vitro efficacy against MRSA whereas doxycyline, clindamycin, trimethoprim-sulfamethoxazole, gentamicin, erthromycin and ciprofloxacin have poor sensitivity.